Danaher said operating profit margin for the 3 months ended March 28, 2025 was 22.2%, down 40 basis points from 22.6% for the 3 months ended March 29, 2024. Product mix, reduced operating leverage, currency exchange rates of 30 basis points, acquired businesses and a product line disposition of 25 basis points, and an impairment charge related to a facility in the Biotechnology segment of 25 basis points unfavorably impacted the comparison.

1. 01

   Danaher said operating profit margin for the 3 months ended March 28, 2025 was 22.2%, down 40 basis points from 22.6% for the 3 months ended March 29, 2024. Product mix, reduced operating leverage, currency exchange rates of 30 basis points, acquired businesses and a product line disposition of 25 basis points, and an impairment charge related to a facility in the Biotechnology segment of 25 basis points unfavorably impacted the comparison.

2. 02

   Danaher said total sales in the Biotechnology segment for the 3 months increased 6.0%, led by core sales growth in the bioprocessing business. Operating profit margin in the segment rose 610 basis points, though the facility impairment charge unfavorably impacted results by 90 basis points.

3. 03

   Danaher said Life Sciences segment sales for the 3 months declined 3.5%, led by core sales decline in the genomics consumables business. Diagnostics segment sales declined 3.0%, and the company cited China's volume-based procurement program and healthcare reimbursement changes as key factors.

4. 04

   Danaher said operating cash flow for the first 3 months of 2025 was approximately $1.3 billion, a decline of 25% or $440 million. Financing activities used approximately $1.3 billion in cash, with share repurchases of approximately $1.1 billion as a principal driver of the increase.

Key figures

Quarter ended March 28, 2025

Revenue

$5.7B

Operating income

$1.3B

Net income

$954M

EPS

$1.32

Gross profit

$3.5B

Operating cash flow

$1.3B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.